Current status and future opportunities for controlling acromegaly.

Area of Science:

• Endocrinology
• Oncology
• Neurosurgery

Background:

• Growth hormone (GH) secreting adenomas cause acromegaly, a condition with significantly increased mortality.
• Effective treatment of acromegaly requires tumor mass reduction and normalization of insulin-like growth factor I (IGF-I) levels.
• Comparing efficacy of existing therapies is challenging due to varied cure criteria.

Purpose of the Study:

• To review and compare the efficacy of current acromegaly treatment modalities based on IGF-I normalization rates.
• To evaluate the effectiveness of novel therapies for acromegaly.

Main Methods:

• Pooled data analysis from acromegaly studies.
• Review of cure rates based on IGF-I normalization for surgery, conventional radiation, and medical therapies (dopamine agonists, somatostatin analogs).
• Assessment of emerging treatments including lanreotide, Gamma Knife radiosurgery, and pegvisomant.

Main Results:

• Reported IGF-I normalization rates: bromocriptine (approx. 10%), cabergoline (34%), conventional radiation (36%), surgery (50-90% for microadenomas, <50% for macroadenomas), octreotide (54-66%).
• Newer therapies show promising results: lanreotide (48% IGF-I normalization), pegvisomant (up to 97% IGF-I normalization).
• Gamma Knife radiosurgery offers improved delivery over conventional radiation but similar cure rates.

Conclusions:

• Current acromegaly treatments achieve variable IGF-I normalization rates.
• Novel therapies, particularly pegvisomant, offer significantly higher rates of IGF-I normalization.
• Standardized criteria for cure are essential for accurate treatment efficacy assessment.